The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
The Phosphodiesterase Type 4 Inhibitor, Rolipram, Enhances Glucocorticoid Receptor Function
Abstract
Previous studies have demonstrated that antidepressants can enhance glucocorticoid receptor (GR) translocation and function, possibly through activation of cAMP and downstream cAMP dependent protein kinases. Accordingly, we examined GR function in cells treated with rolipram, a phosphodiesterase (PDE) type 4 inhibitor that antagonizes cAMP breakdown. Compared with vehicle-treated cells, rolipram alone and in combination with dexamethasone significantly enhanced GR function as measured in both mouse L929 cells and rat C6 glioma cells stably transfected with reporter genes driven by upstream glucocorticoid response elements. Rolipram's facilitation of GR function was reversible by the GR antagonist, RU486, and was associated with reduced cytosloic GR binding, indicating rolipram enhancement of GR nuclear translocation. Finally, rolipram potently augmented GR enhancement by the antidepressant, desipramine. These findings broaden the potential pathways by which PDE type 4 inhibitors can influence cellular function and indicate that these agents may have special utility in disorders associated with impaired GR-mediated feedback inhibition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“these observations are somewhat confounded because nimesulide also inhibits phosphodiesterase (PDE) type IV, and PDE IV inhibitors, like rolipram, have been shown to enhance GR function (see below).70,71”
From Cytokines and Glucocorticoid Receptor Signaling (2009) · cites this paper as [71]
In the citing paper
“Pharmacologic therapies targeting PKA may represent a “double hit” on mechanisms driving glucocorticoid resistance, given that PKA pathways can both enhance GR function and inhibit inflammatory signaling.71”
From Cytokines and Glucocorticoid Receptor Signaling (2009) · cites this paper as [71]
In the citing paper
“We found that the PDE type IV inhibitor, rolipram, which antagonizes the breakdown of cAMP, significantly enhanced GR-mediated gene transcription in LMCAT mouse fibroblast cells and rat C6 glioma cells, both in the presence and absence of DEX.”
From Cytokines and Glucocorticoid Receptor Signaling (2009) · cites this paper as [71]
In the citing paper
“This effect was independent of the p-glycoprotein pump.71”
From Cytokines and Glucocorticoid Receptor Signaling (2009) · cites this paper as [71]
In the citing paper
“Studies by us and others have shown that antidepressants also induce GR nuclear translocation and transactivation, which is, at least in part, mediated by the cyclic AMP (cAMP)/protein kinase A (PKA) cascade.21, 22, 23, 24, 30, 31, 32, 33”
From Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor (2011) · cites this paper as [30]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Corticosteroid Receptor Hypothesis of Depression
Holsboer, F. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00159-7 · Cited by 2,181
Nibuya, M., Nestler, E., & Duman, R. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-07-02365.1996 · Cited by 1,206
Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment
Pariante, C. M., & Miller, A. H. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01088-x · Cited by 1,147 · cited 10×
“6 (cAMP) (Chen and Rasenick 1995a,b; Nestler et al. 1989; Nibuya et al. 1996), there has been speculation that the influence of antidepressants on GR is through their effects on cAMP-related signal transduction events (Pariante and Miller 2001).”
BackgroundInfluentialSelf-citationSickness behavior as a new target for drug development
Kent, S., Bluthé, R.-M., Kelley, K. W., & Dantzer, R. (1992) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(92)90012-u · Cited by 863
Antidepressants and Hypothalamic-Pituitary-Adrenocortical Regulation
HOLSBOER, F., & BARDEN, N. (1996) · Endocrine Reviews · doi:10.1210/edrv-17-2-187 · Cited by 852
Major Depression and Activation of The Inflammatory Response System
Maes, M. (1999) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-585-37970-8_2 · Cited by 617 · cited 2×
“cancer) patients who are depressed (Pariante and Miller 2001; Owens and Nemeroff 1993; Maes 1999; Musselman et al. 2001).”
BackgroundMultiple cyclic nucleotide phosphodiesterases.
Beavo, J. A., Conti, M., & Heaslip, R. J. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09714-7 · Cited by 472
The P-Glycoprotein Efflux Pump: How Does it Transport Drugs?
Sharom, F. J. (1997) · Journal of Membrane Biology · doi:10.1007/s002329900305 · Cited by 458
Musselman, D. L., Miller, A. H., Porter, M. R., Manatunga, A., Gao, F., Penna, S., Pearce, B. D., Landry, J., Glover, S., McDaniel, J. S., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1252 · Cited by 445
Self-citationEickelberg, O., Roth, M., Lörx, R., Bruce, V., Rüdiger, J., Johnson, M., & Block, L.-H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.2.1005 · Cited by 378
Cited by
Raison, C. L., & Miller, A. H. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.9.1554 · Cited by 1,197
Self-citationHaroon, E., Raison, C. L., & Miller, A. H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.205 · Cited by 1,000
Self-citationDepressive disorders and immunity: 20 years of progress and discovery
Irwin, M. R., & Miller, A. H. (2007) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2007.01.010 · Cited by 676
Self-citationPace, T. W. W., Hu, F., & Miller, A. H. (2007) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2006.08.009 · Cited by 621
Self-citationNeuroendocrine-Immune Mechanisms of Behavioral Comorbidities in Patients With Cancer
Miller, A. H., Ancoli-Israel, S., Bower, J. E., Capuron, L., & Irwin, M. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.7805 · Cited by 608
Self-citation
Metadata
- Authors
- Miller, A.
- Affiliations
- Emory University (US)
- Corresponding author
- Miller, A
- Venue
- Neuropsychopharmacology
- Published
- 2002-12
- Volume
- 27
- Issue
- 6
- Pages
- 939-948
- ISSN
- 0893-133X (ISSN-L)
- OpenAlex
- W2060503785
- Cited by
- 57
- References
- 54
- Citations by year
- 2023: 1 · 2017: 2 · 2014: 4 · 2013: 4
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Alliance for Research on Schizophrenia and Depression
- National Institute of Mental Health (MH47674-08, MH-00680, R01MH047674)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Phosphodiesterase function and regulation
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- rolipram, phosphodiesterase-4 inhibitors, glucocorticoid receptor, cAMP signaling, nuclear translocation, dexamethasone, desipramine, antidepressants, glucocorticoid response element, RU486, glucocorticoid feedback inhibition, protein kinase A
- MeSH terms
- Animals, Cell Line, Dose-Response Relationship, Drug, Phosphodiesterase Inhibitors, Receptors, Glucocorticoid, 3',5'-Cyclic-AMP Phosphodiesterases, Rolipram, Mice, Rats, Cyclic Nucleotide Phosphodiesterases, Type 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Phosphodiesterase Type 4 Inhibitor, Rolipram, Enhances Glucocorticoid Receptor Function. https://app.cochat.ai/papers/10.1016/s0893-133x(02)00381-0
- The paper
- Miller, A. (2002). The Phosphodiesterase Type 4 Inhibitor, Rolipram, Enhances Glucocorticoid Receptor Function. Neuropsychopharmacology. https://doi.org/10.1016/s0893-133x(02)00381-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.